Literature DB >> 28202126

[Effect of ulinastatin on serum levels of tumor necrosis factor-α, P-selectin, and thrombin-antithrombin complex in young rats with sepsis].

Yun Liu1, Xing-Heng Wu.   

Abstract

OBJECTIVE: To investigate the effect of ulinastatin (UTI) for early drug intervention on the serum levels of tumor necrosis factor-α (TNF-α), P-selectin, and thrombin-antithrombin complex (TAT) in young rats with sepsis.
METHODS: A total of 120 male rats aged 4 weeks were randomly divided into normal control group, sham-operation group, sepsis group, low-dose UTI group (50 000 U/kg), and high-dose UTI group (200 000 U/kg), with 24 rats in each group. Modified cecal ligation and puncture was performed to establish a rat model of sepsis, and the rats in the low- and high-dose UTI groups were given caudal vein injection of UTI after model establishment. ELISA was used to measure the serum levels of TNF-α, P-selectin, and TAT at 6, 12, and 24 hours after model establishment.
RESULTS: The sepsis group had significant increases in the serum levels of TNF-α, P-selectin, and TAT at 6 hours, and the serum levels of TNF-α and TAT continued to increase by 24 hours (P<0.05); P-selectin reached the peak at 12 hours and decreased slightly at 24 hours (P<0.05). The UTI groups had similar change patterns in the levels of P-selectin and TAT as the sepsis group. The UTI groups had significant increases in the level of TNF-α at 6 hours, but gradually decreased over time. The changes in serum levels of TNF-α, P-selectin, and TAT in the UTI groups were significantly smaller than in the sepsis group (P<0.05). The high-dose UTI group had significantly smaller changes in serum levels of TNF-α, P-selectin, and TAT than the low-dose UTI group (P<0.05).
CONCLUSIONS: Early intervention with UTI can significantly improve coagulation function and inhibit the production of TNF-α, P-selectin, and TAT in young rats with sepsis. High-dose UTI has a significantly greater effect than low-dose UTI.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28202126

Source DB:  PubMed          Journal:  Zhongguo Dang Dai Er Ke Za Zhi        ISSN: 1008-8830


  4 in total

Review 1.  Research progress of ulinastatin in the treatment of liver diseases.

Authors:  Shangping Fang; Pengfei Li; Chenxu Zhu; Xiaoxiao Han; Pengju Bao; Wenjun Guo
Journal:  Int J Clin Exp Pathol       Date:  2020-11-01

2.  ADJunctive Ulinastatin in Sepsis Treatment in China (ADJUST study): study protocol for a randomized controlled trial.

Authors:  Wei Jiang; Xiangyou Yu; Tongwen Sun; Yanfen Chai; Ping Chang; Zhongqing Chen; Jingye Pan; Zhiyong Peng; Ruilan Wang; Xiaozhi Wang; Yuan Xu; Li Yu; Qingshan Zheng; Bin Du
Journal:  Trials       Date:  2018-02-21       Impact factor: 2.279

3.  High-dose ulinastatin to prevent late-onset acute renal failure after orthotopic liver transplantation.

Authors:  Haijin Lv; Xuxia Wei; Xiaomeng Yi; Jianrong Liu; Pinglan Lu; Mi Zhou; Yuling An; Huimin Yi
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

4.  Tumor necrosis factor-α small interfering RNA alveolar epithelial cell-targeting nanoparticles reduce lung injury in C57BL/6J mice with sepsis.

Authors:  Like Qian; Xi Yin; Jiahao Ji; Zhengli Chen; He Fang; Hu Li; Feng Zhu; Fei Chang
Journal:  J Int Med Res       Date:  2021-01       Impact factor: 1.671

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.